PURPOSE: To verify the efficacy of a serum autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 (PHD3) as a serological marker for RCC. METHODS: Serum samples and surgically resected tumor tissue specimens were obtained from 22 patients with primary RCC, 15 of whom underwent radical nephrectomy and 7 partial nephrectomy. Preoperative serum samples were obtained just before tumor resection. Postoperative serum samples were obtained from 17 patients at least 1 month after tumor removal. Serum samples were also obtained from 26 healthy volunteers. Titers of the anti-PHD3 antibody (Ab) were determined by enzyme-linked immunosorbent assay. RESULTS: Serum anti-PHD3 Ab titers were significantly higher in patients with RCC than in healthy volunteers (0.610 ± 0.023 vs. 0.591 ± 0.031, P = 0.0001). Using a cutoff point of 0.599, sensitivity, specificity, and positivity for prediction of RCC were 86.4, 57.7, and 63.3%, respectively. In all 17 patients, titers of serum anti-PHD3 were decreased after the surgical resection compared with those before operation (0.622 ± 0.023 vs. 0.580 ± 0.024, P = 0.0003). CONCLUSIONS: The present study suggests that the anti-PHD3 Ab may be a novel serological marker for RCC and the titer may reflect the tumor burden in each individual.
PURPOSE: To verify the efficacy of a serum autoantibody against hypoxia-inducible factor prolyl hydroxylase-3 (PHD3) as a serological marker for RCC. METHODS: Serum samples and surgically resected tumor tissue specimens were obtained from 22 patients with primary RCC, 15 of whom underwent radical nephrectomy and 7 partial nephrectomy. Preoperative serum samples were obtained just before tumor resection. Postoperative serum samples were obtained from 17 patients at least 1 month after tumor removal. Serum samples were also obtained from 26 healthy volunteers. Titers of the anti-PHD3 antibody (Ab) were determined by enzyme-linked immunosorbent assay. RESULTS: Serum anti-PHD3 Ab titers were significantly higher in patients with RCC than in healthy volunteers (0.610 ± 0.023 vs. 0.591 ± 0.031, P = 0.0001). Using a cutoff point of 0.599, sensitivity, specificity, and positivity for prediction of RCC were 86.4, 57.7, and 63.3%, respectively. In all 17 patients, titers of serum anti-PHD3 were decreased after the surgical resection compared with those before operation (0.622 ± 0.023 vs. 0.580 ± 0.024, P = 0.0003). CONCLUSIONS: The present study suggests that the anti-PHD3 Ab may be a novel serological marker for RCC and the titer may reflect the tumor burden in each individual.
Authors: Anders Larsson; Gunnar Ronquist; Christian Wülfing; Elke Eltze; Olaf Bettendorf; Lena Carlsson; B Ove Nilsson; Axel Semjonow Journal: Urol Oncol Date: 2006 May-Jun Impact factor: 3.498
Authors: Rebecca J Appelhoff; Ya-Min Tian; Raju R Raval; Helen Turley; Adrian L Harris; Christopher W Pugh; Peter J Ratcliffe; Jonathan M Gleadle Journal: J Biol Chem Date: 2004-07-07 Impact factor: 5.157
Authors: Animesh Barua; Michael J Bradaric; Tewabe Kebede; Sara Espionosa; Seby L Edassery; Pincas Bitterman; Jacob Rotmensch; Judith L Luborsky Journal: Am J Reprod Immunol Date: 2007-04 Impact factor: 3.886
Authors: Petra Miikkulainen; Heidi Högel; Fatemeh Seyednasrollah; Krista Rantanen; Laura L Elo; Panu M Jaakkola Journal: J Biol Chem Date: 2019-01-07 Impact factor: 5.157
Authors: A L Pastore; G Palleschi; L Silvestri; D Moschese; S Ricci; V Petrozza; A Carbone; A Di Carlo Journal: Dis Markers Date: 2015-04-02 Impact factor: 3.434
Authors: Heidi Högel; Krista Rantanen; Petra Miikkulainen; Tomi Suomi; Petri Kouvonen; Laura L Elo; Panu M Jaakkola Journal: Cancer Metab Date: 2017-07-04